Background: Cinacalcet rapidly normalizes serum calcium and reduces intact parathyroid hormone (PTH) levels in renal transplant patients with hypercalcaemia and persistent hyperparathyroidism. The aim of this study is to evaluate the 6 months efficacy of cinacalcet and the effect of cinacalcet withdrawal on serum calcium and PTH in such patients. Furthermore, the impact of cinacalcet on bone turnover and quality of life was assessed.
Methods: Twelve renal allograft recipients with hypercalcaemia due to persistent hyperparathyroidism were treated with cinacalcet for 26 weeks. Cinacalcet was then withdrawn to check for recurrence of hypercalcaemia.
Results: Cinacalcet maintained normocalcaemia in all patients from week 4 to 26, and PTH significantly decreased and remained suppressed. Serum phosphate increased, whereas the serum calcium-phosphate product remained unchanged. The excretion of calcium and phosphate in the 24 h urine had tendency to decrease. After cinacalcet was withdrawn, hypercalcaemia recurred rapidly and PTH increased to baseline values. Renal function remained stable, proteinuria was unchanged and no allograft rejection was observed. During treatment with cinacalcet, total and bone-specific alkaline phosphatase increased, whereas the urinary deoxypyridinoline-creatinine ratio did not change significantly, suggesting enhanced bone formation. Quality of life assessed at weeks 10 and 26 remained unchanged compared with baseline.
Conclusions: In conclusion, continued treatment with cinacalcet is required to maintain long-term normocalcaemia and to suppress the enhanced PTH production in renal transplant recipients with persistent hyperparathyroidism.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/ndt/gfl560 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Introduction: After kidney transplantation, persistent hyperparathyroidism commonly occurs, often alongside increased serum calcium levels. It is reasonable to infer that kidney transplant recipients (KTRs) with hypercalcemia related to persistent hyperparathyroidism are more susceptible to developing anemia. However, reports suggest that hypercalcemia could be a contributing factor to erythrocytosis.
View Article and Find Full Text PDFUS-Guided Thermal Ablation for Secondary Hyperparathyroidism: A Prospective Multicenter Study.
Radiology
January 2025
From the Department of Interventional Ultrasound, the Fifth Medical Center, Chinese PLA General Hospital, No. 28 Fuxing Rd, Beijing 100853, China (Y.L., F.Y.L., J.Y., P.L.); Department of Ultrasound, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang, China (C.Z.P.); Graduate Department, Bengbu Medical College, Bengbu, Anhui, China (H.H.C.); Department of Ultrasound, Capital Medical University, Beijing Friendship Hospital, Beijing, China (L.X.Q.); Department of Ultrasonography, Fujian Provincial Hospital, Fuzhou, Fujian, China (S.S.W.); Department of Interventional Medicine, China-Japan Friendship Hospital, Beijing, China (M.A.Y.); Department of Ultrasound, Longyan First Affiliated Hospital of Fujian Medical University, Longyan, China (S.P.L., J.T.Z.); Department of Ultrasound, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China (Y.S.); Weifang Peoples Hospital, Weifang, Shandong, China (C.B.S.); Daqing Oilfield General Hospital, Daqing, Liaoning, China (Z.W.Y., R.Z.); and Department of Ultrasound, First Affiliated Hospital of Dalian Medical University, Dalian, Liaoning, China (Y.C., S.H.G.).
Background Interest in microwave ablation (MWA) and radiofrequency ablation (RFA) use for treating secondary hyperparathyroidism (SHPT) is rising; however, ablation outcomes in patients with SHPT are not well characterized. Purpose To assess the response of parathyroid hormone (PTH), calcium, phosphorus, and alkaline phosphatase (ALP) levels to US-guided parathyroid MWA and RFA and the safety of these treatments in participants with SHPT. Materials and Methods This prospective multicenter cohort study, conducted from September 2017 to March 2022, included participants with SHPT.
View Article and Find Full Text PDFRobotic Resection of an Ectopic Parathyroid Gland: A Systematic Review.
Cureus
December 2024
General Surgery, East Sussex Healthcare NHS Trust, Brighton and Hove, GBR.
Ectopic parathyroid glands result from abnormal migration during development. If not detected promptly, they can lead to persistent or recurrent primary hyperparathyroidism (pHPT). Inferior parathyroid glands are typically located in the anterior mediastinum, while superior parathyroid glands are often near the tracheoesophageal groove, both of which contribute to pHPT.
View Article and Find Full Text PDFLeontiasis ossea in the setting of chronic kidney disease and limited dialysis access: A case report with discussion of therapeutic implications.
Radiol Case Rep
March 2025
Department of Family Medicine, University of South Florida, Morsani College of Medicine, Tampa, FL, USA.
Article Synopsis
- Leontiasis ossea, or craniofacial fibrous dysplasia, is a rare condition that causes abnormal growth of facial bones, often linked to chronic kidney disease and high parathyroid hormone levels.
- A case of a 30-year-old male with severe facial swelling and bone changes highlights the rapid progression of symptoms after poor dialysis access and the persistence of hyperparathyroidism despite treatment efforts.
- The article also reviews the underlying causes, imaging techniques used for diagnosis, and management strategies for this complex disease.
Localization in primary hyperparathyroidism.
Best Pract Res Clin Endocrinol Metab
December 2024
Department of Nuclear Medicine, Post Graduate Institute of Medical Education and Research, Sector 12, Chandigarh 160012, India. Electronic address:
Primary hyperparathyroidism is the main cause of hypercalcemia, resulting predominantly from parathyroid adenomas followed by hyperplasia. Diagnosis relies on clinical and biochemical parameters. Accurate pre-operative localization is mandatory for better surgical outcome.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!